Drugplain

PRAMIPEXOLE 1 mg/1

PRAMIPEXOLE · TABLET · Camber Pharmaceuticals, Inc.

10 Recalls on Record
Plain English

Pramipexole is a prescription tablet taken by mouth that is used to treat symptoms of Parkinson's disease and restless legs syndrome. It works by stimulating dopamine receptors in the brain to help improve movement and reduce uncomfortable sensations in the legs.

Key Facts

Brand Name
PRAMIPEXOLE
Generic Name
PRAMIPEXOLE
NDC Code (Product)
31722-910
Manufacturer
Camber Pharmaceuticals, Inc.
Strength
1 mg/1
Dosage Form
TABLET
Route
ORAL
Marketing Status
Application #
ANDA203855
Marketing Start
08/01/2015

Recall History

10 Recalls on Record
Class III08/21/2019

Macleods Pharma Usa Inc

Subpotent Drug: Out of specification result during stability study in Pramipexole Dihydrochloride Tablets 0.125 mg

TerminatedVoluntary: Firm initiated
Class II05/13/2019

American Health Packaging

GMP Deviations; possible cross contamination of product due to cleaning procedure failure.

TerminatedVoluntary: Firm initiated
Class II05/06/2019

Zydus Pharmaceuticals USA Inc

CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.

TerminatedVoluntary: Firm initiated
Class II07/02/2013

Aidapak Services, LLC

Labeling:Label Mixup; PRAMIPEXOLE DI-HCL, Tablet, 1.5 mg may be potentially mislabeled as LIOTHYRONINE SODIUM, Tablet, 25 mcg, NDC 42794001902, Pedigree: AD68010_11, EXP: 5/28/2014.

TerminatedVoluntary: Firm initiated
Class II07/02/2013

Aidapak Services, LLC

Labeling: Label Mixup; PRAMIPEXOLE DI-HCL, Tablet, 1 mg may be potentially mislabel as MISOPROSTOL, Tablet, 200 mcg, NDC 59762500801, Pedigree: W003117, EXP: 6/13/2014.

TerminatedVoluntary: Firm initiated
Class III03/07/2019

Boehringer Ingelheim Pharmaceuticals, Inc.

Failed Tablet/Capsule Specifications: identification of low weight tablets during routine stability testing.

TerminatedVoluntary: Firm initiated
Class II05/06/2019

Zydus Pharmaceuticals USA Inc

CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.

TerminatedVoluntary: Firm initiated
Class II05/06/2019

Zydus Pharmaceuticals USA Inc

CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.

TerminatedVoluntary: Firm initiated
Class II05/13/2019

American Health Packaging

GMP Deviations; possible cross contamination of product due to cleaning procedure failure.

TerminatedVoluntary: Firm initiated
Class II05/06/2019

Zydus Pharmaceuticals USA Inc

CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.

TerminatedVoluntary: Firm initiated

Side Effects Reported to FDA

FDA FAERS database · These are reported events, not confirmed side effects

drug ineffective1,822 reports
fatigue1,390 reports
fall1,355 reports
nausea1,109 reports
pain1,059 reports
condition aggravated1,026 reports
off label use1,009 reports
hallucination969 reports
dizziness968 reports
dyspnoea931 reports

Full Prescribing Information

Source: FDA Drug Label (SPL)For healthcare professionals

Indications & Usage

1 INDICATIONS AND USAGE Pramipexole dihydrochloride extended-release tablets are indicated for the treatment of Parkinson's disease. Pramipexole dihydrochloride extended-release tablet is a non-ergot dopamine agonist indicated for the treatment of Parkinson’s disease (PD) (1)

Dosage & Administration

2 DOSAGE AND ADMINISTRATION Pramipexole dihydrochloride extended-release tablets are taken once daily, with or without food (2.1) Tablets must be swallowed whole and must not be chewed, crushed, or divided (2.1) Starting dose is 0.375 mg given once daily (2.2) Dose may be increased gradually, not more frequently than every 5 to 7 days, first to 0.75 mg per day and then by 0.75 mg increments up to a maximum recommended dose of 4.5 mg per day. Assess therapeutic response and tolerability at a minimal interval of 5 days or longer after each dose increment. (2.2) Patients may be switched overnight from immediate-release pramipexole tablets to extended-release pramipexole tablets at the same daily dose. Dose adjustment may be needed in some patients (2.3) Pramipexole dihydrochloride extended-release tablets should be discontinued gradually. (2.2) 2.1 General Dosing Considerations Pramipexole dihydrochloride extended-release tablets are taken orally once daily, with or without food. Pramipexole dihydrochloride extended-release tablets must be swallowed whole and must not be chewed, crushed, or divided. If a significant interruption in therapy with pramipexole dihydrochloride extended-rel

Contraindications

4 CONTRAINDICATIONS None. None (4)

Drug Interactions

7 DRUG INTERACTIONS Dopamine antagonists: May diminish the effectiveness of pramipexole (7.1). 7.1 Dopamine Antagonists Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of pramipexole dihydrochloride extended-release tablets.

Adverse Reactions

6 ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in other sections of the labeling: Falling Asleep During Activities of Daily Living and Somnolence [see Warnings and Precautions (5.1) ] Symptomatic Orthostatic Hypotension [see Warnings and Precautions (5.2) ] Impulse Control / Compulsive Behaviors [see Warnings and Precautions (5.3) ] Hallucinations and Psychotic-like Behavior [see Warnings and Precautions (5.4) ] Dyskinesia [see Warnings and Precautions (5.5) ] Postural Deformity [see Warnings and Precautions ( 5.6 ) ] Rhabdomyolysis [see Warnings and Precautions (5.8) ] Retinal Pathology [see Warnings and Precautions (5.9) ] Events Reported with Dopaminergic Therapy [see Warnings and Precautions (5.10) ] Withdrawal Symptoms [see Warnings and Precautions ( 5.11 )] Most common adverse reactions (incidence ≥5% and greater than placebo) : Early PD without levodopa: somnolence, nausea, constipation, dizziness, fatigue, hallucinations, dry mouth, muscle spasms, and peripheral edema (6.1) Advanced PD with levodopa: dyskinesia, nausea, constipation, hallucinations, headache, and anorexia (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Dr. Reddy’s L

Frequently Asked Questions

What is PRAMIPEXOLE used for?

Pramipexole is a prescription tablet taken by mouth that is used to treat symptoms of Parkinson's disease and restless legs syndrome. It works by stimulating dopamine receptors in the brain to help improve movement and reduce uncomfortable sensations in the legs.

Is PRAMIPEXOLE a controlled substance?

PRAMIPEXOLE is not classified as a controlled substance by the DEA.

What is the generic name for PRAMIPEXOLE?

The generic name for PRAMIPEXOLE is PRAMIPEXOLE. There are 11 other brand versions of PRAMIPEXOLE.

What is the NDC code for PRAMIPEXOLE 1 mg/1?

The NDC (National Drug Code) for PRAMIPEXOLE 1 mg/1 is 31722-910, listed by Camber Pharmaceuticals, Inc..